Optimization of a 1,5-dihydrobenzo[b][1,4] diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: Addressing configurational instability through scaffold modification
Optimization of a 1,5-dihydrobenzo[b][1,4] diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: Addressing configurational instability through scaffold modification
复制标题
DOI:
10.1016/j.bmcl.2013.03.073
复制
发表时间:
2013-06-01
影响因子:
2.7
通讯作者:
Simoneau, Bruno
中科院分区:
文献类型:
--
作者:
Fader, Lee D.;Landry, Serge;Simoneau, Bruno
The optimization of a 1,5-dihydrobenzo[b][1,4] diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly that possess a labile stereocenter at C3 is described. Quaternization of the C3 position of compound 1 in order to prevent racemization gave compound 2, which was inactive in our capsid disassembly assay. A likely explanation for this finding was revealed by in silico analysis predicting a dramatic increase in energy of the bioactive conformation upon quaternization of the C3 position. Replacement of the C3 of the diazepine ring with a nitrogen atom to give the 1,5-dihydro-benzo[f][1,3,5]-triazepine-2,4-dione analog 4 was well tolerated. Introduction of a rigid spirocyclic system at the C3 position gave configurationally stable 1,5-dihydrobenzo[b][1,4] diazepine-2,4-dione analog 5, which was able to access the bioactive conformation without a severe energetic penalty and inhibit capsid assembly. Preliminary structure-activity relationships (SAR) and X-ray crystallographic data show that knowledge from the 1,5-dihydrobenzo[ b][1,4] diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly can be transferred to these new scaffolds. (C) 2013 Elsevier Ltd. All rights reserved.